logo
logo

Convergent Therapeutics announced it raised $29.2 Million in an initial filing from an offering of $99.2 Million

May 22, 2023about 2 years ago

Amount Raised

$29.2 Million

CambridgeBiotechnologyHealth CareTherapeutics

Company Information

Company

Convergent Therapeutics

Location

Cambridge, Massachusetts, United States

About

Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People